Bristol-Myers Squibb, Bluebird Bio Release Results of KarMMa Phase 2 Study

   By Stephen Nakrosis

Bristol-Myers Squibb Co. (BMY) and bluebird bio Inc. (BLUE) said results from a Phase 2 study of their idecabtagene vicleucel treatment for certain myeloma patients met its primary endpoint and key secondary endpoint.

Idecabtagene vicleucel, or ide-cel, is an investigational treatment for certain patients with relapsed and refractory multiple myeloma, the companies said.

The KarMMa Phase 2 study "met its primary endpoint and key secondary endpoint, demonstrating deep and durable responses in a heavily pre-treated multiple myeloma patient population," the companies said.

The companies said they are "are actively preparing for submission of these data to health authorities for proposed initial registration of ide-cel as a first-in-class BCMA-targeted CAR T cell therapy."

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

December 06, 2019 17:15 ET (22:15 GMT)

Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024